Patent Assignment
Reel/Frame 071108/0692
Security Interest
Recorded: 2025-05-14
Pages: 10
Assignee
HERCULES CAPITAL, INC., AS AGENT
1 NORTH B STREET, SUITE 2000, SAN MATEO, CALIFORNIA, 94401
Covered Properties
(26)
Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids Using a Glp-1R and Gcgr Agonist
PCT:
PCT/US2025/019462 ↗
Peptide Pharmaceuticals for Insulin Resistance
Peptide Pharmaceuticals
Improved Peptide Pharmaceuticals
Peptide Pharmaceuticals for Insulin Resistance
Improved Peptide Pharmaceuticals for Insulin Resistance
Peptide Pharmaceuticals for Insulin Resistance
Peptide Pharmaceuticals
Improved Peptide Pharmaceuticals
Application:
16/579,799 →
Publication:
US 2021/0077629
Improved Peptide Pharmaceuticals for Insulin Resistance
Application:
16/826,208 →
Publication:
US 2020/0289653
Improved Peptide Pharmaceuticals for Treatment of Nash and Other Disorders
Peptide Pharmaceuticals
Application:
17/031,583 →
Publication:
US 2022/0348611
GLP-1R and GCGR Agonists, Formulations, and Methods of Use
Application:
17/180,827 →
Publication:
US 2021/0290732
Peptide Pharmaceuticals for Insulin Resistance
Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
Peptide Pharmaceuticals for Treatment of Nash and Other Disorders
Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
Application:
18/467,608 →
Publication:
US 2024/0269238
Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
Application:
18/503,065 →
Publication:
US 2024/0277815
Glp-1R, Gip-R and/or Gcgr Agonists, Formulations, and Methods of Use
Application:
18/547,160 →
Publication:
US 2024/0148879
Peptide Pharmaceuticals for Insulin Resistance
Peptide Pharmaceuticals for Insulin Resistance
Application:
18/943,440 →
Publication:
US 2025/0136656
Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
Application:
18/943,449 →
Publication:
US 2025/0134963
Peptide Pharmaceuticals for Insulin Resistance
Application:
18/988,066 →
Publication:
US 2025/0313604
Peptide Pharmaceuticals for Treatment of Nash and Other Disorders
Application:
19/030,991 →
Publication:
US 2025/0281450
GLP-1R and GCGR Agonists, Formulations, and Methods of Use
Application:
19/034,251 →
Publication:
US 2025/0262280
Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist
Application:
19/076,984 →
Publication:
US 2025/0288650
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 20, 2013
From: NESTOR, JOHN J.
To: MEDERIS DIABETES, LLC
Reel/Frame 031639/0525 →
Assignment of Assignor's Interest
Nov 20, 2013
From: NESTOR, JOHN J.
To: EUMEDERIS PHARMACEUTICALS, INC.
Reel/Frame 031639/0517 →
Assignment of Assignor's Interest
Jun 24, 2015
From: NESTOR, JOHN J.
To: EUMEDERIS PHARMACEUTICALS, INC.
Reel/Frame 036016/0858 →
Assignment of Assignor's Interest
Jun 24, 2015
From: NESTOR, JOHN J.
To: MEDERIS DIABETES, LLC
Reel/Frame 036016/0860 →
Assignment of Assignor's Interest
Nov 20, 2017
From: NESTOR, JOHN J.
To: SPITFIRE PHARMA, INC.
Reel/Frame 044183/0041 →
Assignment of Assignor's Interest
Nov 20, 2017
From: NESTOR, JOHN J.
To: SPITFIRE PHARMA, INC.
Reel/Frame 044182/0962 →
Assignment of Assignor's Interest
Nov 21, 2017
From: NESTOR, JOHN J.
To: SPITFIRE PHARMA, INC.
Reel/Frame 044194/0772 →
Assignment of Assignor's Interest
Jun 1, 2018
From: NESTOR, JOHN J.
To: EUMEDERIS PHARMACEUTICALS, INC.
Reel/Frame 045963/0694 →
Assignment of Assignor's Interest
Jul 20, 2019
From: SPITFIRE PHARMA INC.
To: MEDERIS DIABETES INC.
Reel/Frame 049809/0931 →
Assignment of Assignor's Interest
Jul 20, 2019
From: EUMEDERIS PHARMACEUTICALS INC.
To: MEDERIS DIABETES INC.
Reel/Frame 049809/0925 →
Assignment of Assignor's Interest
Jun 26, 2020
From: SPITFIRE PHARMA INC.
To: MEDERIS DIABETES LLC
Reel/Frame 053059/0865 →
Assignment of Assignor's Interest
Jul 7, 2020
From: NESTOR, JOHN
To: SPITFIRE PHARMA INC
Reel/Frame 053135/0049 →
Corrective Assignment to Correct the Application Number Previously Recorded at Reel: 053135 Frame: 0049. Assignor(S) Hereby Confirms the Assignment.
Dec 9, 2020
From: NESTOR, JOHN J
To: SPITFIRE PHARMA INC
Reel/Frame 054660/0673 →
Assignment of Assignor's Interest
Feb 24, 2021
From: KRISHNAN, VYJAYANTHI
To: SPITFIRE PHARMA LLC
Reel/Frame 055397/0852 →
Assignment of Assignor's Interest
Feb 24, 2021
From: NESTOR, JOHN
To: SPITFIRE PHARMA LLC
Reel/Frame 055393/0741 →
Assignment of Assignor's Interest
Feb 25, 2023
From: JAMES, JOYCE; HARRIS, SCOTT; KRISHNAN, VYJAYANTHI; OLHAYE, OMAR ROBLE
To: SPITFIRE PHARMA LLC
Reel/Frame 062803/0290 →
Assignment of Assignor's Interest
Jun 19, 2023
From: SPITFIRE PHARMA LLC
To: MEDERIS DIABETES, LLC
Reel/Frame 063985/0868 →
Assignment of Assignor's Interest
Nov 29, 2023
From: ROBERTS, M SCOT; HARRIS, MATTHEW SCOTT
To: SPITFIRE PHARMA LLC
Reel/Frame 065701/0301 →
Assignment of Assignor's Interest
Nov 29, 2023
From: SUSCHACK, JOHN JOSEPH, III
To: SPITFIRE PHARMA LLC
Reel/Frame 065697/0666 →
Assignment of Assignor's Interest
Dec 5, 2023
From: GEORGES, BERTRAND VICTOR GILBERT
To: SPITFIRE PHARMA LLC
Reel/Frame 065762/0988 →
Assignment of Assignor's Interest
Dec 5, 2023
From: BROWNE, SARAH K.
To: SPITFIRE PHARMA LLC
Reel/Frame 065772/0208 →
Assignment of Assignor's Interest
Feb 17, 2025
From: NESTOR, JOHN J.
To: SPITFIRE PHARMA, INC.
Reel/Frame 070240/0338 →
Affidavit of Address Change
Feb 17, 2025
From: MEDERIS DIABETES, LLC
To: MEDERIS DIABETES LLC
Reel/Frame 070240/0403 →
Assignment of Assignor's Interest
Feb 19, 2025
From: NESTOR, JOHN J.
To: EUMEDERIS PHARMACECUTICALS, INC.
Reel/Frame 070261/0624 →
Assignment of Assignor's Interest
Feb 19, 2025
From: NESTOR, JOHN J.
To: EUMEDERIS PHARMACECUTICALS, INC.
Reel/Frame 070267/0942 →